Clinical trials: Cabozantinib
Merkel Cell Carcinoma, Skin Cancer
Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma
This is an open-label, non-randomized, phase 2 study to assess the feasibility of using cabozantinib in recurrent/metastatic Merkel Cell Carcinoma patients that progressed after platinum-based therapy.
- Trial name
- NCT02036476
- Testing
- Cabozantinib
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Dana-Farber Cancer Institute
High Grade Osteosarcoma, Localized Osteosarcoma
A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma
This phase II/III trial tests the safety, side effects, and best dose of the drug cabozantinib in combination with standard chemotherapy, and to compare the effect of adding cabozantinib to standard chemotherapy alone in treating…
- Conditions
- High Grade Osteosarcoma, Localized Osteosarcoma, Metastatic Osteosarcoma, Secondary Osteosarcoma
- Trial name
- NCT05691478
- Testing
- Bone Scan, Cabozantinib S-malate, Cisplatin
- Where
- 202 sites in United States, Australia and 2 more
- Volunteers
- 1,122 people
- Sponsor
- National Cancer Institute (NCI)
Esophageal Cancer, Metastatic Cancer
Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
To demonstrate that combination of cabozantinib and atezolizumab is safe and efficacious in patients with recurrent/metastatic esophageal squamous cell carcinoma.
- Conditions
- Esophageal Cancer, Metastatic Cancer, Squamous Cell Carcinoma
- Trial name
- NCT05007613
- Testing
- Cabozantinib 40 MG, Atezolizumab Injection
- Where
- Taiwan
- Volunteers
- 24 people
- Sponsor
- National Taiwan University Hospital
Differentiated Thyroid Cancer (DTC), Poorly Differentiated Thyroid Cancer
A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting
Phase II, non-randomized, open-label study to determine the efficacy of cabozantinib as a firstline treatment for patients with differentiated thyroid cancer (DTC). Subjects will receive drug at a starting dose of 60mg PO QD.
- Trial name
- NCT02041260
- Testing
- Cabozantinib
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Thomas Jefferson University
Rare Tumor, Refractory Tumor
Efficacy and Safety of Precision Therapy in Refractory Tumor
This study is intended to evaluate efficacy and safety of targeted precision therapy in patients with refractory tumor, including rare tumor without standard recommended treatment and common tumor after multiple line of therapy.
- Trial name
- NCT03239015
- Testing
- Gefitinib, Erlotinib, Afatinib
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Baodong Qin
Hepatocellular Carcinoma Non-resectable, Metastatic Hepatocellular Carcinoma
Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment
Patients suffering from advanced stage hepatocellular carcinoma (HCC) who have shown disease progression during lenvatinib-based first line treatment, will be enrolled in this trial.
- Trial name
- NCT04511455
- Testing
- Cabozantinib
- Where
- 10 sites in Germany
- Volunteers
- 22 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Differentiated Thyroid Cancer
Impact of BRAFV600E Intratumor Heterogeneity in Thyroid Cancer Treated With Tyrosine Kinase Inhibitors
Background: BRAFV600E is the most frequent oncogene in differentiated thyroid cancer (DTC) occurring in about 50% of cases. Clinical trials with tyrosine kinase inhibitors (TKI) with specific activity against BRAF in metastatic…
- Trial name
- NCT01700699
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- University of Salerno
Non Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer
Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma
This study will combine cabozantinib with pemetrexed to treat patients with non-small cell lung cancer, urothelial cancer and advanced malignant mesothelioma.
- Conditions
- Non Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer, Urothelial Carcinoma, Malignant Mesothelioma
- Trial name
- NCT04173338
- Testing
- Cabozantinib, Pemetrexed
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Augusta University
Renal Cell Cancer, Kidney Neoplasm
Primary Tumor Ablation and Outcome in Metastatic Renal Cell Carcinoma Treated With Immunotherapy Combinations.
This is Phase IV, randomized, multi arm, multicenter, low interventional clinical trial, aiming to evaluate if treatment of primary tumor in mRCC patients with initial benefit to anti-PD1- based therapy (SOC) can improve the…
- Conditions
- Renal Cell Cancer, Kidney Neoplasm, Immunotherapy, Kidney Cancer
- Trial name
- ITALIC-RCC (NCT06903312)
- Testing
- Deferred Cytoreductive Nephrectomy + medical treatment, Radiotherapy + medical treatment, Medical therapy
- Where
- Italy
- Volunteers
- 409 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Urothelial Cancer
Niraparib in Combination with Cabozantinib (XL184) in Patients with Advanced Urothelial Cancer (NICARAGUA)
Cabozantinib is an oral, small-molecule tyrosine kinase inhibitor. Its primary targets are Hepatocyte growth factor receptor protein (MET), vascular endothelial growth factor receptor 1-3 (VEGFR1-3), RET, AXL, FLT3 and KIT.
- Trial name
- NICARAGUA (NCT03425201)
- Testing
- Niraparib plus Cabozantinib
- Where
- 10 sites in Spain
- Volunteers
- 67 people
- Sponsor
- Fundacion CRIS de Investigación para Vencer el Cáncer
Metastatic Ewing Sarcoma
Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes
This single arm study is designed to demonstrate the feasibility of a radically different approach for an exceptionally high-risk subset of MES with widely metastatic disease (WMES).
- Trial name
- METTSEO (NCT07194044)
- Testing
- Vincristine, Doxorubicin, Cyclophosphamide
- Where
- 21 sites in United States
- Volunteers
- 15 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
High Grade Neuroendocrine Neoplasms
Cabozantinib in High Grade Neuroendocrine Neoplasms
High grade neuroendocrine neoplasm patients are treated with platinum doublets such as carboplatin and etoposide mimicking the current guidelines for small cell lung cancer (SCLC).
- Trial name
- NCT04412629
- Testing
- Cabozantinib, Blood for plasma biomarkers, Tissue biopsy
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Washington University School of Medicine
Renal Cell Cancer, Renal Cell Carcinoma
A Study to Describe the Kidney Cancer Patient Population Treatment, and Results in the Hospital District of Southwest Finland.
The purpose of the study is to find out how patients with advanced kidney cancer have been treated in the hospital district of Southwest Finland over time.
- Conditions
- Renal Cell Cancer, Renal Cell Carcinoma, Cancer of Kidney, Cancer of the Kidney
- Trial name
- NCT05363072
- Where
- Finland
- Volunteers
- 1,112 people
- Sponsor
- Pfizer
Skin Angiosarcoma, Skin Radiation-Related Angiosarcoma
Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma
This phase II trial studies how well paclitaxel with and without nivolumab works in treating patients with soft tissue sarcoma that have not received taxane drugs, and how well nivolumab and cabozantinib work in treating taxane…
- Conditions
- Skin Angiosarcoma, Skin Radiation-Related Angiosarcoma, Visceral Angiosarcoma
- Trial name
- NCT04339738
- Testing
- Biospecimen Collection, Cabozantinib S-malate, Computed Tomography
- Where
- 171 sites in United States, Guam
- Volunteers
- 90 people
- Sponsor
- National Cancer Institute (NCI)
BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma
This phase II trial tests whether yttrium Y 90 glass microspheres, atezolizumab, and cabozantinib work to shrink tumors in patients with liver cancer (hepatocellular carcinoma) that cannot be removed by surgery (unresectable) or…
- Conditions
- BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Locally Advanced Hepatocellular Carcinoma, Recurrent Hepatocellular Carcinoma
- Trial name
- NCT05327738
- Testing
- Atezolizumab, Biopsy, Cabozantinib S-malate
- Sponsor
- OHSU Knight Cancer Institute
Lung Neuroendocrine Neoplasm, GEP Neuroendocrine Tumor
A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM)
The aim of CABOTEM study is to demonstrate the safety and activity of the Cabozantinib and Temozolomide combination in Lung and GEP-NENs patients, progressing after a first line therapy, including target therapies (everolimus…
- Trial name
- CABOTEM (NCT04893785)
- Testing
- Cabozantinib and Temozolomide
- Where
- Italy
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute, Naples
Clear Cell RCC
A Clinical Gene Therapy Study With Hematopoietic Stem Cells for the Treatment, With Single Dose of Temferon, of Patients Suffering From Metastatic Renal Cell Carcinoma
This is an open label, single-centre phase 1/2 study involving a single dose of Temferon, an investigational Advanced Therapy Medicinal Product (ATMP), to treat patients with metastatic clear cell renal cell carcinoma (RCC) with…
- Trial name
- TEM-GU (NCT06716853)
- Testing
- Temferon, Pembrolizumab, Cabozantinib
- Where
- Italy
- Volunteers
- 10 people
- Sponsor
- Genenta Science
Clear Cell Renal Cell Carcinoma, Solid Tumors
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
The purpose of this study is to evaluate the safety and tolerability of: casdatifan when taken alone in participants with advanced solid tumor malignancies and clear cell renal cell carcinoma (ccRCC) during the dose escalation…
- Trial name
- ARC-20 (NCT05536141)
- Testing
- casdatifan, Cabozantinib, Zimberelimab
- Where
- 25 sites in United States, Australia and 2 more
- Volunteers
- 362 people
- Sponsor
- Arcus Biosciences, Inc.
Metastatic Renal Cell Carcinoma, Brain Metastases
A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the Brain
The purpose of this study is to find out whether the combination of cabozantinib, nivolumab, and radiation therapy is a safe and effective treatment that causes few or mild side effects in people with renal cell cancer that has…
- Trial name
- NCT06132945
- Testing
- Cabozantinib, Nivolumab, Stereotactic Radiosurgery (SRS)
- Where
- 7 sites in United States
- Volunteers
- 2 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Renal Cell Carcinoma
Intensified Monitoring of PhArmacology of Cabozantinib as a Tool for Toxicity Management in Patients With Renal Cell Carcinoma
Adverse events (AEs) with Cabozantinib are frequent (about 40-67% of patients) and often lead to temporary treatment interruptions, dose reductions or permanent discontinuations, potentially reducing dose intensity and sustained…
- Trial name
- IMPACT (NCT07805122)
- Testing
- Intensified Monitoring of Pharmacology
- Where
- Italy
- Volunteers
- 216 people
- Sponsor
- Centro di Riferimento Oncologico - Aviano